Back to Search Start Over

C/EBPα Regulates FOXC1 to Modulate Tumor Growth by Interacting with PPARγ in Hepatocellular Carcinoma

Authors :
Zhuo Xu
Rui-Feng Tang
Shao-Hua Meng
Jian-Guo Bai
Zhao-Lin Yin
Li-Li Zhao
Chao Sun
Guang-Jun Ma
Jun-Wei Ji
Wei Yang
Source :
Current Cancer Drug Targets. 20:59-66
Publication Year :
2020
Publisher :
Bentham Science Publishers Ltd., 2020.

Abstract

Background: Forkhead box C1 (FOXC1) is an important cancer-associated gene in tumor. PPAR-γ and C/EBPα are both transcriptional regulators involved in tumor development. Objective: We aimed to clarify the function of PPAR-γ, C/EBPα in hepatocellular carcinoma (HCC) and the relationship of PPAR-γ, C/EBPα and FOXC1 in HCC. Methods: Western blotting, immunofluorescent staining, and immunohistochemistry were used to evaluate protein expression. qRT-PCR was used to assess mRNA expression. Co-IP was performed to detect the protein interaction. And ChIP and fluorescent reporter detection were used to determine the binding between protein and FOXC1 promoter. Results: C/EBPα could bind to FOXC1 promoter and PPAR-γ could strengthen C/EBPα’s function. Expressions of C/EBPα and PPAR-γ were both negatively related to FOXC1 in human HCC tissue. Confocal displayed that C/EBPα was co-located with FOXC1 in HepG2 cells. C/EBPα could bind to FOXC1 promoter by ChIP. Luciferase activity detection exhibited that C/EBPα could inhibit FOXC1 promoter activity, especially FOXC1 promoter from -600 to -300 was the critical binding site. Only PPAR-γ could not influence luciferase activity but strengthen inhibited effect of C/EBPα. Further, the Co-IP displayed that PPAR-γ could bind to C/EBPα. When C/EBPα and PPAR-γ were both high expressed, cell proliferation, migration, invasion, and colony information were inhibited enormously. C/EBPα plasmid combined with or without PPAR-γ agonist MDG548 treatment exhibited a strong tumor inhibition and FOXC1 suppression in mice. Conclusion: Our data establish C/EBPα targeting FOXC1 as a potential determinant in the HCC, which supplies a new pathway to treat HCC. However, PPAR-γ has no effect on FOXC1 expression.

Details

ISSN :
15680096
Volume :
20
Database :
OpenAIRE
Journal :
Current Cancer Drug Targets
Accession number :
edsair.doi.dedup.....84a02f384b7511bb8077791151cacb88
Full Text :
https://doi.org/10.2174/1568009619666190912161003